UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2023
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
+45 70 20 27 28
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-232693 and 333-262970) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | |
| | |
| BY: | /s/ Anthony Pagano |
| | Name: Anthony Pagano |
| | Title: Executive Vice President & Chief Financial Officer |
DATE: May 31, 2023
EXHIBIT INDEX
Exhibit | Description of Exhibit |
| |
99.1 | Company Announcement Dated May 31, 2023: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons |
Exhibit 99.1
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
Company Announcement
COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.
The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.
Please find below a statement of such trading in shares issued by Genmab A/S
1. | Details of the person discharging managerial responsibilities / | ||
a) | Name | Jan van de Winkel | |
2. | Reason for the notification | | |
a) | Position/status | President and Chief Executive Officer | |
b) | Initial notification/Amendment | Initial notification | |
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Genmab A/S | |
b) | LEI-code | 529900MTJPDPE4MHJ122 | |
4. | Details of the transaction(s): section to be repeated for | ||
a) | Description of the financial | Share
DK0010272202 | |
b) | Nature of the transaction | Sale of Shares | |
c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | DKK 2,744.00 | 64 |
| | DKK 2,744.50 | 62 |
| | DKK 2,745.00 | 529 |
| | DKK 2,746.00 | 6,641 |
| | DKK 2,746.50 | 94 |
| | DKK 2,747.00 | 404 |
| | DKK 2,748.00 | 117 |
| | DKK 2,749.00 | 448 |
| | DKK 2,749.50 | 62 |
| | DKK 2,750.00 | 139 |
| | DKK 2,751.00 | 153 |
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 29 |
Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 1/4 |
21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
| | DKK 2,753.00 | 65 |
| | DKK 2,754.00 | 260 |
| | DKK 2,755.00 | 57 |
| | DKK 2,755.50 | 74 |
| | DKK 2,756.00 | 326 |
| | DKK 2,757.00 | 96 |
| | DKK 2,757.50 | 62 |
| | DKK 2,758.00 | 68 |
| | DKK 2,759.00 | 120 |
| | DKK 2,759.50 | 132 |
| | DKK 2,760.00 | 62 |
| | DKK 2,761.00 | 200 |
| | DKK 2,762.00 | 340 |
| | DKK 2,763.00 | 36 |
| | DKK 2,764.00 | 489 |
| | DKK 2,764.50 | 62 |
| | DKK 2,765.00 | 313 |
| | DKK 2,766.00 | 473 |
| | DKK 2,767.00 | 259 |
| | DKK 2,768.00 | 69 |
| | DKK 2,769.00 | 65 |
| | DKK 2,770.00 | 127 |
| | DKK 2,771.00 | 106 |
| | DKK 2,772.00 | 299 |
| | DKK 2,773.00 | 539 |
| | DKK 2,774.00 | 444 |
| | DKK 2,775.00 | 199 |
| | DKK 2,775.50 | 32 |
| | DKK 2,776.00 | 208 |
| | DKK 2,777.00 | 267 |
| | DKK 2,777.50 | 8 |
| | DKK 2,778.00 | 31 |
| | DKK 2,779.00 | 312 |
| | DKK 2,780.00 | 110 |
| | DKK 2,781.00 | 109 |
| | DKK 2,782.00 | 126 |
| | DKK 2,782.50 | 31 |
| | DKK 2,783.00 | 56 |
| | DKK 2,784.00 | 62 |
| | DKK 2,786.00 | 68 |
| | DKK 2,787.00 | 119 |
| | DKK 2,788.00 | 201 |
| | DKK 2,789.00 | 98 |
| | DKK 2,790.00 | 41 |
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 29 |
Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 2/4 |
21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
| | DKK 2,793.00 | 186 |
| | DKK 2,795.50 | 440 |
| | DKK 2,796.00 | 161 |
| | DKK 2,797.00 | 377 |
| | DKK 2,797.50 | 341 |
| | DKK 2,798.00 | 220 |
| | DKK 2,799.00 | 248 |
| | DKK 2,800.00 | 164 |
| | DKK 2,801.00 | 312 |
| | DKK 2,802.00 | 369 |
| | DKK 2,802.50 | 30 |
| | DKK 2,803.00 | 23 |
| | DKK 2,804.00 | 129 |
| | DKK 2,805.00 | 244 |
| | DKK 2,806.00 | 56 |
| | DKK 2,806.50 | 124 |
| | DKK 2,807.00 | 128 |
| | DKK 2,808.00 | 62 |
| | DKK 2,808.50 | 30 |
| | DKK 2,809.00 | 333 |
| | DKK 2,810.00 | 185 |
| | DKK 2,811.00 | 176 |
| | DKK 2,811.50 | 30 |
| | DKK 2,812.00 | 62 |
| | DKK 2,813.00 | 158 |
| | DKK 2,814.00 | 103 |
| | DKK 2,816.00 | 60 |
| | DKK 2,820.00 | 188 |
| | DKK 2,824.00 | 127 |
d) | Aggregated information -Aggregated volume -Price | 21,000 DKK 2,768.11 | |
e) | Date of the transaction | 2023-05-30 | |
f) | Place of the transaction | Aquis Exchange Europe (AQEA, AQED and AQEU) CBOE Europe (BEUP, CEUD and CEUX) Nasdaq Copenhagen (DCSE and XCSE) SIGMA (SGMV) Turquoise Europe (TQEM and TQEX) | |
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 29 |
Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 3/4 |
21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |
Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons
biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.
Genmab A/S | Tel: +45 7020 2728 | Company Announcement no. 29 |
Kalvebod Brygge 43 | Fax: +45 7020 2729 | Page 4/4 |
21560 Copenhagen V, Denmark | www.genmab.com | CVR no. 2102 3884 |
| | LEI Code 529900MTJPDPE4MHJ122 |